Insight Molecular Diagnostics Inc.

Summary of Risk Factors

We face many risks and uncertainties, as more fully described in this section under the heading Item 1A. “Risk Factors.” Some of these risks and uncertainties are summarized below. The summary below does not contain all of the information that may be important to you, and you should read this summary together with the more detailed discussion of these risks and uncertainties contained in “Risk Factors.”

Summary - Risks Related to Our Capital Resources

•

We have incurred operating losses since inception, and we do not know if we will attain profitability.

•

We have historically been dependent upon outside financing capital to fund our operations and until such time as our revenues are sufficient to finance our operating expenses, we may need to issue additional equity or debt securities to raise the capital needed to pay our operating expenses.

•

We may incur significant cash payment and common stock issuance obligations under our agreements arising from our investments in IGI and Chronix.

Summary - Risks Related to Our Business Operations

•

Our revenues in the near term will depend on our ability to commercialize a small number of diagnostic tests.

•

The research and development work we are doing is costly, time consuming, and uncertain as to its results.

•

Increased competition from, and technological advances by, our competitors could negatively affect our operating results.

•

Sales of our diagnostic tests could be adversely impacted by the reluctance of physicians to adopt the use of our tests and by the availability of competing diagnostic tests.

•

Defects, failures or quality issues associated with our products could lead to product recalls or safety alerts, adverse regulatory actions, product liability lawsuits and other litigation and negative publicity. If we are unable to obtain or maintain sufficient insurance, a product liability claim against us could adversely affect our business.

•

We have limited capital, marketing, sales, and regulatory compliance resources for the commercialization of our diagnostic tests.

•

We may face technology transfer challenges and expenses in adding new tests to our portfolio and in expanding our reach into new geographical areas on new instrument platforms.

•

If our laboratory facilities become damaged or inoperable, or we are required to vacate any facility, our ability to provide services and pursue our research and development and commercialization efforts may be jeopardized.

•

There is a limited number of manufacturers of molecular diagnostic testing equipment and related chemical reagents necessary for the provision of our diagnostic tests.

•

If we fail to enter into and maintain successful strategic alliances for diagnostic tests that we elect to co-develop, co-market, or out-license, we may have to reduce or delay our diagnostic test development or increase our expenditures.

•

We are, and may become, dependent on collaborations to develop and commercialize our diagnostic test candidates and to provide the manufacturing, regulatory compliance, sales, marketing and distribution capabilities required for the success of our business.

•

Our business could be adversely affected if we lose the services of the key personnel upon whom we depend.

•

Our business and operations could suffer in the event of system failures.

•

Security breaches and other disruptions could compromise our information and expose us to liability, and could cause our business and reputation to suffer.

•

Failure of our internal control over financial reporting could harm our business and financial results.

•

We are subject to laws and regulations governing corruption, which may require us to develop, maintain, and implement costly compliance programs.

•

We may become subject to litigation, which could harm our stock price, business, results of operations and financial condition.

•

We may undertake strategic acquisitions in the future, and difficulties integrating such acquisitions could damage our ability to achieve or sustain profitability.

•

Our business could be adversely impacted by inflation.

Summary - Risks Related to Our Industry

•

Our operations as a clinical laboratory in the United States are subject to oversight by CMS under CLIA, as well as certain state agencies, and our operation of clinical laboratories in any foreign jurisdictions are subject to similar regulatory oversight. Any failure to maintain our CLIA or applicable state or international permits and licenses may affect our ability to commercialize our diagnostic tests.

•

While we believe our LDTs are within the scope of the FDA’s enforcement discretion policy, and therefore not required to obtain clearance or approval before commercialization, the FDA may attempt to regulate LDTs in the future, which could lead to LDT product development delays and increased costs.

•

We currently market certain IVDs for RUO that have not been cleared by the FDA in reliance on the regulatory exemption for IVDs intended for RUO, but if the FDA determines that our RUO tests do not meet the applicable requirements for exemption or have intended uses that are inconsistent with RUO tests, we may be required to suspend commercialization of such products until we can obtain the requisite FDA clearance and/or subject to FDA warning or untitled letters, seizure, injunction, fines, or other enforcement action.

•

We will need to obtain FDA and other regulatory approvals for any IVDs that we may develop in order to market those IVD tests, and we may not be able to obtain those regulatory approvals in a timely manner or at all.

•

Our ability to commercialize our products is dependent on availability and sufficiency of third-party payer coverage and our ability to ensure our tests remain reimbursed or attain reimbursement by Medicare, and the loss of, or a significant reduction in, reimbursement from Medicare or the CMS would have a material adverse impact on our business.

•

Clinical trial failures can occur at any stage of the testing and we may experience numerous unforeseen events during, or as a result of, the clinical trial process that could delay or prevent commercialization of our current or future diagnostic tests.

•

Changes in healthcare laws may have a material adverse effect on our financial condition, results of operations and cash flows.

•

Because of certain Medicare billing policies, we may not receive complete reimbursement for tests provided to Medicare patients.

•

Long payment cycles of Medicare, Medicaid and other third-party payers, or other payment delays, could hurt our cash flows and increase our need for working capital.

•

Private health insurance company policies may deny coverage or limit reimbursement for the performance of our diagnostic tests.

•

We will be required to comply with federal and state laws governing the privacy of health information, and any failure to comply with these laws could result in material criminal and civil penalties.

•

We are subject to numerous federal and state statutes and regulations pertaining to our business and are subject to government oversight and scrutiny for our compliance with such laws. Laboratory and health care regulatory compliance efforts are expensive and time-consuming, and failure to maintain compliance with applicable laws could result in enforcement action which could be detrimental to our business.

•

Tariff policies and potential countermeasures could increase our costs and disrupt our global supply chain, which could negatively impact the results of our operations.

Summary - Risks Related to Intellectual Property

•

We rely on patents and trade secrets, and our financial success will depend, in part, on our ability to obtain commercially valuable patent claims, protect our intellectual property rights and operate without infringing upon the proprietary rights of others.

•

We may not be able to obtain patent protection for our diagnostic tests if our pending U.S. patent applications are found to be directed to unpatentable subject matter.

•

Changes to the patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our diagnostic tests.

•

Other companies or organizations may challenge our patent rights or may assert patent rights that prevent us from developing and commercializing our diagnostic tests.

•

If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected, and our business would be harmed.

•

We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful.

•

We may not be able to enforce our intellectual property rights throughout the world.

•

If we are sued for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our diagnostic tests.

•

Failure to adequately protect, or disputes relating to, trademarks or patents, could harm our business.

•

Patent terms may be inadequate to protect our competitive position on our diagnostic tests for an adequate amount of time.

•

Obtaining and maintaining patent protection depends on compliance with various procedures and other requirements, and our patent protection could be reduced or eliminated in case of non-compliance with these requirements.

Summary - Risks Related to Our Common Stock

•

The trading price of our common stock is highly volatile, and purchasers of our common stock could incur substantial losses.

•

Because we do not pay dividends, our stock may not be a suitable investment for anyone who needs to earn dividend income.

•

Securities analysts may not cover our common stock, and this may have a negative impact on the market price of our shares.

•

You may experience dilution of your ownership interests if we issue additional shares of common stock or preferred stock.

•

We are a “smaller reporting company” under the SEC’s disclosure rules and have elected to comply with the reduced disclosure requirements applicable to smaller reporting companies.

•

Failure to establish and maintain adequate finance infrastructure and accounting systems and controls could impair our ability to comply with the financial reporting and internal controls requirements for publicly traded companies.

•

Failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a delisting of our common stock.